NEW YORK (GenomeWeb News) – Danish genomics and molecular diagnostics firm Exiqon today reported that its third-quarter revenues rose 11 percent year over year.

The company posted sales of DKK30.1 million ($5.2 million) in the quarter ended Sept. 30, up from DKK27.1 million a year ago. Product sales totaled DKK20.7 million, up from DKK19.3 million a year ago. Service revenues were down slightly to DKK5.1 million from DKK5.3 million, and license-based revenues were up to DKK2.1 million from DKK1.2 million. Contract research revenues rose to DKK2.2 million from DKK1.4 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.